Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.

There is no information available on the relation between response to chemotherapy and the high-risk phenotype assessed by uPA and/or PAI-1. The clinical situation of neoadjuvant chemotherapy provides a means of rapidly assessing the sensitivity of the primary tumour to cytotoxic drug regimens. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Pierga, J. Y., Lainé-Bidron, C., Beuzeboc, P., De Crémoux, P., Pouillart, P., Magdelénat, H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2227990/
https://www.ncbi.nlm.nih.gov/pubmed/9275033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2227990/
https://www.ncbi.nlm.nih.gov/pubmed/9275033

Ejemplares similares